Literature DB >> 23626904

Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

Edward A Pankey1, Matthew Epps, Bobby D Nossaman, Albert L Hyman, Philip J Kadowitz.   

Abstract

Pulmonary arterial hypertension (PAH) is a devastating disease with limited therapeutic options. Moreover, when PAH occurs in patients diagnosed with systemic sclerosis, worse outcomes are observed. The purpose of this review is to discuss the etiologies of PAH found in the systemic sclerosis patient, limitations of current medical therapies, and, finally, potential therapies for patients with this combination.

Entities:  

Keywords:  connective tissue disease; pulmonary arterial hypertension; pulmonary hypertension; systemic sclerosis

Year:  2010        PMID： 23626904      PMCID： PMC3636503     

Source DB:  PubMed          Journal:  J Clin Rheumatol Musculoskelet Med        ISSN： 2043-0248


  170 in total

Review 1.  Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis.

Authors:  John Varga
Journal:  Arthritis Rheum       Date:  2002-07

2.  Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.

Authors:  Karen C Patterson; Ariel Weissmann; Tahamtan Ahmadi; Harrison W Farber
Journal:  Ann Intern Med       Date:  2006-07-18       Impact factor: 25.391

Review 3.  Mechanisms of vascular damage in systemic sclerosis.

Authors:  Ulf Müller-Ladner; Oliver Distler; Lidia Ibba-Manneschi; Elena Neumann; Steffen Gay
Journal:  Autoimmunity       Date:  2009-11       Impact factor: 2.815

4.  Therapies for scleroderma-related pulmonary arterial hypertension.

Authors:  Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2009       Impact factor: 3.772

Review 5.  Scleroderma--demographics and survival.

Authors:  A J Silman
Journal:  J Rheumatol Suppl       Date:  1997-05

6.  Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.

Authors:  S M Palmer; L J Robinson; A Wang; J R Gossage; T Bashore; V F Tapson
Journal:  Chest       Date:  1998-01       Impact factor: 9.410

7.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  David B Badesch; Nicholas S Hill; Gary Burgess; Lewis J Rubin; Robyn J Barst; Nazzareno Galiè; Gerald Simonneau
Journal:  J Rheumatol       Date:  2007-11-01       Impact factor: 4.666

8.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Authors:  Stephen C Mathai; Laura K Hummers; Hunter C Champion; Fredrick M Wigley; Ari Zaiman; Paul M Hassoun; Reda E Girgis
Journal:  Arthritis Rheum       Date:  2009-02

Review 9.  Pathology of pulmonary arterial hypertension.

Authors:  Rubin M Tuder
Journal:  Semin Respir Crit Care Med       Date:  2009-07-24       Impact factor: 3.119

Review 10.  Systemic sclerosis at the cellular level: molecular pathways of pathogenesis and its implication on future drug design.

Authors:  S W Schulz; C T Derk
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.